Showing results (1-10 of 205) with videos related to
Sort By:
Pageof 21
Case Reports in Oncological Medicine|April 10, 2019
Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active MelanomaUmang Swami, Brian Swick, Yousef Zakharia, et al.Critical Reviews in Oncology/Hematology|January 22, 2019
Advanced stage melanoma therapies: Detailing the present and exploring the futureChelsea Luther, Umang Swami, Jun Zhang, et al.Journal of Oncology|August 21, 2019
Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse EventsUmang Swami, Varun Monga, Aaron D Bossler, et al.Melanoma Research|August 8, 2018
Toxicities with targeted therapies after immunotherapy in metastatic melanomaNicole Grogan, Umang Swami, Aaron D Bossler, et al.Annals of Translational Medicine|July 19, 2021
Current status of intralesional agents in treatment of malignant melanomaMisam Zawit, Umang Swami, Hassan Awada, et al.Cancers|December 11, 2019
Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic ReviewAustin Greco, Danish Safi, Umang Swami, et al.Oncology Research and Treatment|March 31, 2020
A Retrospective Analysis of Clinical Trial Accrual of Patients Presented in a Multidisciplinary Tumor Board at a Tertiary Health Care Center and Associated BarriersErin M Mobley, Umang Swami, Sarah Mott, et al.Melanoma Research|March 5, 2019
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanomaUmang Swami, Varun Monga, Michele Freesmeier, et al.Cancers|February 22, 2018
A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced SarcomasVarun Monga, Umang Swami, Munir Tanas, et al.Pituitary|July 22, 2019
Ipilimumab-induced hypophysitis, a single academic center experienceTravis Snyders, Daniel Chakos, Umang Swami, et al.Pageof 21